MAYO CLINIC
Mayo Medical Laboratories

Laboratory Service Report **1-800-533-1710**

Patient Name	**Patient ID**	**Age**	**Gender**	**Order #**
SAMPLEREPORT,BCRAB	SA00058905	47	F	SA00058905
Ordering Phys CLIENT,CLIENT				**DOB** 06/10/1966
Client Order # SA00058905	**Account Information**			**Report Notes**
Collected 06/10/2013 00:00	C7028846-DLMP Rochester 3050 Superior Drive Rochester, MN 55901			
Printed 06/11/2013 09:10				

Test	Flag	Results	Unit	Reference Value	Perform Site*
BCR/ABL, p210, Quant, Monitor					
RECEIVED: 06/11/2013 08:51 **REPORTED:** 06/11/2013 09:00					
Specimen Type		Peripheral blood			MCR
Final Diagnosis:					MCR

Peripheral blood, BCR/ABL mRNA level analysis (p210 fusion form):

Positive. BCR/ABL p210 mRNA transcripts were detected and estimated to represent 20.0% of total abl (%bcr/abl(p210):abl).

20.0% bcr/abl(p210):abl in this assay is equivalent to 52.8% on the International Scale in which 0.1% is considered a major molecular response in CML (see Branford et al, Blood 2008;112:3330).

Signing Pathologist: Melissa Tricker-Klar
Method summary - BCR/ABL, p210 fusion: p210 mRNA transcript level was evaluated using quantitative, reverse transcription PCR. The assay detects the two most common fusion forms in chronic myelogenous leukemia: e13/a2 and e14/a2, which code for p210 proteins. It is intended for monitoring patients with neoplasms known to carry the p210 fusion form. The assay does not detect other fusions, including those for the p190 protein commonly present in acute lymphoblastic leukemia. This assay should not be used in the diagnostic setting, as it does not detect all bcr/abl fusion forms. If this has been ordered in a diagnostic setting and the result is negative, test #89006 (BCR/ABL mRNA Detection, RT-PCR, Qualitative, Diagnostic) should be ordered to evaluate for all possible fusion forms. Please contact the lab at 1-507-266-0489 with questions or if additional testing is required. See the Mayo Medical Laboratories Interpretive Handbook for method details.

Typical clinical samples have detection limits ranging from 0.01% to 0.0001% bcr/abl:abl. Most CML patients at diagnosis have a bcr/abl:abl result in the range of 20% to 100%.

The reproducibility of this assay is such that results within 0.5 log should be considered equivalent. Trends in the level of BCR/ABL mRNA should be followed and clinically significant changes verified with a subsequent specimen.
Laboratory developed test.

* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.